A phase II trial of RP 5063 in patients with pulmonary arterial hypertension (PAH)
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs RP 5063 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 17 Oct 2017 According to a Reviva Pharmaceuticals media release, this trial is expected to begin in early 2018.
- 29 May 2017 New trial record
- 22 May 2017 According to a Reviva Pharmaceuticals media release, the company anticipates to start this trial in the second half of 2017.